Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | WNT3A | P56704 | 4/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492661 | 0.89 | WNT3A (0.57) | MAPK1WNT3AROCK2ROCK1PORCN | |
| SCHEMBL2185694 | 0.84 | WNT3A (0.79) | WNT3APORCNPSEN1PSEN2APH1B | |
| SCHEMBL1492776 | 0.83 | WNT3A (0.52) | MAPK1WNT3AROCK2ROCK1PORCN | |
| SCHEMBL7964488 | 0.83 | ROCK2 (0.62) | MAPK1WNT3AROCK2ROCK1PSEN1 | |
| SCHEMBL7964831 | 0.83 | ROCK2 (0.58) | MAPK1WNT3AROCK2ROCK1PORCN | |
| SCHEMBL1492962 | 0.80 | WNT3A (0.56) | MAPK1WNT3AROCK2ROCK1PORCN | |
| SCHEMBL7968556 | 0.79 | NAMPT (0.59) | WNT3AROCK2PORCNPSEN1PSEN2 | |
| SCHEMBL1492799 | 0.79 | PRMT3 (0.59) | WNT3AROCK2ROCK1PORCNPSEN1 | |
| SCHEMBL1492739 | 0.79 | ROCK2 (0.53) | MAPK1WNT3AROCK2ROCK1PORCN | |
| SCHEMBL1492896 | 0.79 | WNT3A (0.52) | WNT3AROCK2ROCK1PORCNPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083794-A | Urea compounds as gamma secretase modulators | AMGEN INC | 2011-06-01 | — | — | CN | claimed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | claimed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | MAPK1 3550/4885WNT3A 2435/4885ROCK2 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.